hunter-presents-zebrafish-rare-disease-models-and-ai-drug-screening-platform-at-hope-for-rare-science-conference, hunter-presents-zebrafish-rare-disease-models-and-ai-drug-screening-platform-at-hope-for-rare-science-conference, /news
Inquiry
hunter-presents-zebrafish-rare-disease-models-and-ai-drug-screening-platform-at-hope-for-rare-science-conference, hunter-presents-zebrafish-rare-disease-models-and-ai-drug-screening-platform-at-hope-for-rare-science-conference, 
Inquiry

Hunter Presents Zebrafish Rare Disease Models and AI Drug Screening Platform at Hope for Rare Science Conference

2026/06/27

Hunter Presents Zebrafish Rare Disease Models and AI Drug Screening Platform at Hope for Rare Science Conference

Hunter Laboratory joined the 3rd Hope for Rare Science Conference — also known as the China Rare Disease Research Conference — in Shanghai from June 25 to 27, 2026. Organized by the Ruiou Public Welfare Foundation and co-hosted by the National Children's Medical Center, Children's Hospital of Fudan University, and the CORD Rare Disease Center, the event brought together more than 150 leading experts from 15 countries and over 1,000 researchers and industry professionals. Hunter Laboratory presented its Zebrafish Rare Disease Model Development and Rapid AI Drug Screening and Validation Platform, alongside original research conducted on an autism-related zebrafish gene editing model.

Opening ceremony of the 3rd Hope for Rare Science Conference in Shanghai

The Challenge Facing Rare Disease Research

During the conference opening, Huang Rufang, Founder and Secretary-General of the Ruiou Public Welfare Foundation, highlighted a persistent reality: more than 95% of rare diseases worldwide still have no effective treatment options. Establishing biologically relevant disease models, identifying druggable genetic targets, and running early-stage compound screening all require significant time and specialized resources — challenges that are especially acute when patient populations are small and disease mechanisms are poorly understood.

For rare disease drug discovery, the ability to move quickly from gene identification to functional validation and in vivo compound testing can make a meaningful difference. Purpose-built zebrafish rare disease model platforms offer one practical path forward, combining the biological relevance of an intact living organism with the throughput advantages that early-stage drug screening demands.

CHD8 Autism Research: Key Findings from the Conference Poster

Hunter Laboratory presented a scientific poster titled "CHD8 Deficiency Induces Autism-Like Phenotypes in Zebrafish Crispant Models." The study used CRISPR-based zebrafish gene editing to generate an F0 mosaic crispant model carrying a CHD8 loss-of-function mutation. CHD8 — Chromodomain Helicase DNA-Binding Protein 8 — is widely recognized as one of the strongest genetic risk genes for autism spectrum disorder (ASD), though the downstream biological mechanisms connecting CHD8 deficiency to neurodevelopmental abnormalities are not yet fully characterized.

Using this zebrafish rare disease model, Hunter Laboratory's research team identified three categories of findings:

  • Disrupted glial cell development. A significant increase in astrocyte-related signals and an upward trend in oligodendrocyte-related signals were observed. Both cell types play critical roles in supporting neuronal development and maintaining the neural environment — disruptions in these populations may indicate that CHD8 deficiency interferes with the cellular conditions required for normal brain development.
  • Impaired inhibitory neuronal signaling. Localized reductions in inhibitory neuronal activity were observed in the forebrain region, suggesting disruption of the excitation-inhibition balance that has been widely studied as a contributing mechanism in ASD-related neural network abnormalities.
  • Autism-relevant behavioral and structural phenotypes. The CHD8-deficient zebrafish displayed impaired social behavior, repetitive or stereotyped movements, and observable changes in brain structure consistent with established ASD research criteria.
CHD8-deficient zebrafish crispant model developed for autism-related research

This zebrafish disease model provides an in vivo platform for investigating CHD8-related mechanisms and evaluating potential therapeutic candidates through high-throughput compound screening — a practical complement to cell-based and mammalian model approaches.

The Zebrafish AI Drug Screening and Validation Platform

Hunter Laboratory also showcased its broader Zebrafish Rare Disease Model Development and Rapid AI Drug Screening and Validation Platform. The platform integrates zebrafish gene editing, AI-assisted virtual compound screening, in vivo biological validation, and organoid-based confirmation into a continuous drug discovery workflow — allowing researchers to move from disease gene identification to early compound prioritization and in vivo efficacy testing within a single connected system.

The core workflow includes:

  • Identification and functional validation of disease-associated genes
  • Investigation of relevant molecular pathways and disease mechanisms
  • AI-assisted virtual screening of candidate compounds
  • Development of zebrafish disease models or gene reporter models
  • High-throughput in vivo compound screening and efficacy evaluation
  • Further validation using organoid systems where applicable

By pairing computational compound prioritization with rapid zebrafish in vivo testing, the platform reduces the number of candidates that need to advance into more resource-intensive stages — a meaningful advantage in rare disease drug discovery where project timelines and budgets are often constrained.

Hunter Laboratory's zebrafish rare disease model and AI drug screening platform

Why Zebrafish Are Well-Suited for Rare Disease Drug Discovery

Zebrafish share a large proportion of conserved genes, biological pathways, organs, and physiological processes with humans, making them biologically relevant for studying human genetic conditions. Their embryos are optically transparent, enabling real-time observation of developmental, neural, vascular, and morphological changes in living animals at a level of detail that is difficult to achieve with other model organisms at equivalent throughput.

From a practical standpoint, zebrafish offer several specific advantages for rare disease research:

  • Rapid generation of gene-edited rare disease models
  • High-throughput compound administration and in vivo drug screening
  • Short experimental cycles with lower compound consumption per test
  • Quantifiable behavioral and morphological endpoints
  • Direct visualization of living biological processes in real time
  • Compatibility with automated imaging and behavioral analysis systems

These properties make zebrafish particularly practical for early-stage rare disease drug discovery — helping research teams identify phenotype-rescuing compounds and establish preliminary efficacy evidence before committing to longer and more costly mammalian model stages.

Hunter Laboratory's Technical Services and Research Track Record

Hunter Laboratory's technical services span functional validation of disease-associated genes, zebrafish gene editing disease model development, AI-assisted virtual compound screening, in vivo efficacy validation, early safety and toxicity evaluation, and support for gene therapy and precision medicine research. To date, Hunter Laboratory has completed more than 12,000 research projects for over 3,000 clients and partners — a body of work that reflects extensive hands-on experience across zebrafish model types, experimental designs, phenotype readouts, and data analysis workflows.

Hunter Laboratory presenting zebrafish disease modeling and AI drug screening at the conference

Hunter Laboratory's participation in the 3rd Hope for Rare Science Conference reflects the growing role of zebrafish gene editing and AI drug screening in rare disease research. As researchers worldwide work toward closing the treatment gap for rare genetic conditions, Hunter Laboratory remains committed to advancing its zebrafish rare disease model capabilities and integrated drug screening services — supporting faster, more reliable pathways from genetic target identification to validated therapeutic candidate.

Popular News

Hunter Laboratory Technology (Hangzhou) Co., Ltd. Completes First Official Southeast Asia Showcase at InaLab 2026 Jakarta, Chinese Zebrafish Lab Equipment Gains Global Recognition Overview of InaLab 2026 – The Most Influential Laboratory Instrument Exhibi

Hunter Laboratory Technology (Hangzhou) Co., Ltd. Completes First Official Southeast Asia Showcase at InaLab 2026 Jakarta, Chinese Zebrafish Lab Equipment Gains Global Recognition Overview of InaLab 2026 – The Most Influential Laboratory Instrument Exhibi

2026/08/07

From July 28 to July 30, 2026, the 4th Indonesia International Laboratory Equipment, Analytical Instruments & Services Exhibition (InaLab 2026) grandly opened at Jakarta International Expo Convention Center, a landmark professional event covering...

Hunter Co-Authors Chinese Group Standard for Zebrafish Housing Laboratory Construction

Hunter Co-Authors Chinese Group Standard for Zebrafish Housing Laboratory Construction

2026/07/05

Hunter Laboratory co-authored T/CALAS 126-2024, a Chinese standard for zebrafish housing laboratory construction, covering layout, systems, and operations.

Zebrafish Safety Screening Supports the Development of NMPA-Approved Adamgammadex Sodium Injection

Zebrafish Safety Screening Supports the Development of NMPA-Approved Adamgammadex Sodium Injection

2026/07/01

Hunter Laboratory's zebrafish safety screening identified safety differences during preclinical development of NMPA-approved Adamgammadex Sodium Injection.

Hunter Zebrafish Laboratory Equipment Project Recognized at an Internationally Advanced Level

Hunter Zebrafish Laboratory Equipment Project Recognized at an Internationally Advanced Level

2025/08/11

Hunter Laboratory's zebrafish laboratory equipment was recognized at an internationally advanced level by a 7-member expert panel in Hangzhou, August 2025.

Related Insights

Explore more resources combining zebrafish equipment advances and laboratory best practices to broaden your research horizons.

Zebrafish Imaging Solutions

Zebrafish Imaging Solutions

Discover innovative tools that enhance zebrafish experiment efficiency and accuracy, supporting diverse applications across medical and cosmetic research.

Read More
Data Management in Labs

Data Management in Labs

Learn how digital platforms transform the management and traceability of experimental data, ensuring greater reliability for academia and health companies.

Learn More
Application in Drug Testing

Application in Drug Testing

See how zebrafish equipment is applied in the screening and evaluation processes of pharmaceuticals, advancing efficient pre-clinical research in laboratories.

View Details
hunter presents zebrafish rare disease models and ai drug screening platform at hope for rare science conference-1

Technical Support & Services

Comprehensive solutions for laboratory and industrial equipment, including rapid installation, calibration, remote troubleshooting, and on-site maintenance. Our specialists ensure seamless operation for research labs and commercial clients.

  • Installation & Training
  • Calibration Services
  • 24/7 Remote Support
  • On-site Maintenance
hunter presents zebrafish rare disease models and ai drug screening platform at hope for rare science conference-2

Get a Free Quote

Our representative will contact you soon.
Email
Mobile/WhatsApp
Name
Company Name
Message
0/1000